SynthesisJournal of neurology2026
The clinical, radiological and genetic spectrum AARS2-related leukoencephalopathy: a case series of 15 patients and review of the literature.
Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAARS2-related leukoencephalopathy is a rare autosomal recessive leukodystrophy with overlapping clinical and radiological features with CSF1R-related disease but distinct genetic and phenotypic characteristics. Since its description in 2014, fewer than 60 cases have been reported.
methodsWe conducted a multicentre retrospective case series of individuals with genetically confirmed AARS2-related leukoencephalopathy, integrating clinical, radiological, and molecular data from 15 newly identified patients. Neuroimaging was reviewed by experienced neuroradiologists, and variants were classified using ACMG criteria. A systematic literature review identified 56 additional cases.
resultsAcross 71 individuals, mean age at onset was 27.3 years (range 0-57), with balanced sex distribution. Psychiatric and cognitive symptoms predominated early, affecting 70% and 86% of patients. Pyramidal signs (82%), gait disturbance (80%), and extrapyramidal motor features (45%) were common, whilst seizures occurred in 10%. Premature ovarian failure was reported in 82% of females. Sixteen individuals (22.5%) had childhood onset. Neuroimaging showed confluent frontoparietal white matter abnormalities, corpus callosum thinning, and multifocal diffusion abnormalities. Seventy-two unique AARS2 variants were identified, including seven novel variants. Missense variants predominated. Notably, variants previously linked only to infantile cardiomyopathy, including p.Arg592Trp, were observed.
conclusionsAARS2-related leukoencephalopathy is clinically and genetically heterogeneous with characteristic imaging and broad onset. Recognition of defining features is essential for diagnosis, and genomic testing should be prioritised. This study provides the most comprehensive characterisation to date and suggests genotype-phenotype separation between cardiomyopathy- and leukodystrophy-associated variants may not be absolute.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.